Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole Exome Sequencing of Bladder Cancer Clinical Cohorts

ABSTRACT: Whole Exome Sequencing of Bladder Cancer Clinical Cohorts

PROVIDER: PRJNA254087 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Whole Exome Sequencing of Colorectal Cancer Epidemiologic Cohorts

Project description:Whole Exome Sequencing of Colorectal Cancer Epidemiologic Cohorts

| PRJNA239536 | ENA

Profiling of Colon Cancer Clinical Cohorts

Project description:Profiling of Colon Cancer Clinical Cohorts

| PRJNA261769 | ENA

Molecular characterizaion of neuroendocrine-like bladder cancer

Project description:Neuroendocrine bladder cancer is an aggressive variant of bladder cancer with significant metastatic potential and high risk of mortality. Diagnosis of these tumors is currently dependent on morphological criteria and staining for neuroendocrine markers. Using machine learning and multiple validation cohorts in different clinical settings, we developed a model that identifies tumors with transcriptomic profiles consistent with NE bladder cancers with an absence of NE features by morphological criteria. Early and accurate identification of these patients by genomic analysis may improve outcomes through treatment intensification and adaptation of standard treatment regimens.

2019-03-23 | GSE128702 | GEO

ATM Loss and Therapeutic Vulnerabilities in Bladder Cancer

Project description:ATM plays a central role in the cellular response to DNA damage and ATM alterations are common in several tumor types including bladder cancer. However, the specific impact of ATM alterations on therapy response in bladder cancer is uncertain. Here, we combine preclinical modeling and clinical analyses to comprehensively define the impact of ATM alterations in bladder cancer. We show that ATM loss is sufficient to increase sensitivity to DNA damaging agents including cisplatin and radiation. Furthermore, ATM loss drives sensitivity to DNA repair targeted agents including PARP and ATR inhibitors. ATM loss alters the immune microenvironment and improves anti-PD1 response in preclinical bladder models but is not associated with improved anti-PD1/PD-L1 response in clinical cohorts. Finally, we show that ATM expression by IHC is strongly correlated with response to chemoradiotherapy. Together these data define a potential role for ATM as a predictive biomarker in bladder cancer.

2023-11-24 | GSE232850 | GEO

Whole transcriptome sequencing of chemotherapy-resistant muscle-invasive urothelial bladder cancer

Project description:To identify the therapeutic targets in a treatment-refractroy cancer patient, we performed single-cell RNA sequencing for 3,115 cells from primary bladder cancer (BC159-T#3) and patient-derived xenografts (BC159-T#3-PDX-vehicle and BC159-T#3-PDX-tipifarnib). Matched time-series bulk tumor tissues were also sequenced using whole exome target probe (WES) and whole transcriptome target probe (WTS).

2020-03-26 | GSE145139 | GEO

Homo sapiens

Project description:Whole Exome Sequencing of Bladder Cancer Clinical Cohorts

| PRJNA254088 | ENA

Clinical Sequencing: Whole Exome Sequencing of CLL8 Cohort

Project description:Clinical Sequencing: Whole Exome Sequencing of CLL8 Cohort

| PRJNA285277 | ENA

Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer

Project description:Bladder cancer is one of the most common cancer types worldwide and is characterized by a high rate of recurrence. Previous studies have demonstrated that plasminogen activator inhibi-tor-1 (PAI1) plays an important role in bladder cancer development. The aim of our retrospective study was to assess the effects of PAI1 mutational status in bladder tumors. In this study, we evaluated the mutational status of PAI1 in a series of independent cohorts, comprised of a total of 660 subjects. We identified two clinically relevant 3’ untranslated region (UTR) single nucleotide polymorphisms (SNPs) in PAI1. Caucasian patients with at least one of the SNPs had high risk of recurrence and shorter survival. Additional studies using cell lines demonstrated that one SNP increased the anti-apoptotic effect of PAI1, and another lose the control of cancer cellular growth. This study underscores the relevance and influence of these SNPs in bladder cancer.

2024-01-29 | GSE224309 | GEO

NHLBI GO-ESP: Lung Cohorts Exome Sequencing Project (Asthma)

Project description:NHLBI GO-ESP: Lung Cohorts Exome Sequencing Project (Asthma)

| PRJNA76017 | ENA

NHLBI GO-ESP: Heart Cohorts Exome Sequencing Project (CARDIA)

Project description:NHLBI GO-ESP: Heart Cohorts Exome Sequencing Project (CARDIA)

| PRJNA75741 | ENA